Clinical trials: Relapsed and Refractory Multiple Myeloma
Multiple Myeloma
Study of Tabalumab (LY2127399) in Japanese Participants With Relapsed or Refactory Multiple Myeloma
The purpose of this study is to evaluate the safety and effect on the body of Tabalumab (LY2127399) in combination with bortezomib and dexamethasone in Japanese participants with relapsed or refractory multiple myeloma (MM).
- Trial name
- NCT01556438
- Testing
- Tabalumab, Bortezomib IV, Bortezomib SC
- Where
- 5 sites in Japan
- Volunteers
- 16 people
- Sponsor
- Eli Lilly and Company
Multiple Myeloma
To Evaluate the Safety and Efficacy of Human Derived Anti-BCMA CAR-T Injection for Subjects with R/R MM
This study is a single-arm, open-label, dose-escalation trial to explore the safety, tolerability and pharmacokinetic/pharmacodynamics characteristics of Human Derived anti-BCMA CAR-T Injection , and to preliminarily observe the…
- Trial name
- NCT05302648
- Testing
- Human Derived anti-BCMA CAR-T Injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Hrain Biotechnology Co., Ltd.
Multiple Myeloma
TKI258 in Subjects With Refractory or Relapsed Multiple Myeloma
The primary objective of this study is to determine the maximum tolerated dose (MTD), dose limiting toxicity (DLT), and safety profile of CHIR-258 when administered to subjects with refractory or relapsed multiple myeloma (MM).
- Trial name
- NCT00243763
- Testing
- TKI258
- Where
- 5 sites in United States
- Volunteers
- 64 people
- Sponsor
- Novartis
Multiple Myeloma
Immunotherapy With BCMA CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma
This study is aimed to evaluate the safety, feasibility and efficacy of BCMA CAR-T in the treatment of relapsed or refractory multiple myeloma
- Trial name
- NCT04447573
- Testing
- BCMA CAR-T
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
Refractory Multiple Myeloma, Relapsed Multiple Myeloma
A Study Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple Myeloma
This is a first-in-human Phase I, open-label, multicenter, global, dose-escalation study designed to evaluate the safety, tolerability, and pharmacokinetics of RO7297089 and make a preliminary assessment of anti-tumor activity in…
- Trial name
- NCT04434469
- Testing
- RO7297089
- Where
- 10 sites in Australia, Belgium and 2 more
- Volunteers
- 27 people
- Sponsor
- Genentech, Inc.
Solid Tumors, Adult, Multiple Myeloma
Study of VP301 in Patients With Multiple Myeloma, Lymphoma, or Solid Tumors
This study will test the safety, tolerability, and pharmacokinetics of VP301 in patients with relapsed or refractory multiple myeloma, lymphoma, or solid tumors.
- Conditions
- Solid Tumors, Adult, Multiple Myeloma, Lymphoma
- Trial name
- NCT05698888
- Testing
- VP301
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Virtuoso BINco, Inc.
Multiple Myeloma
Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma
This is a phase 1a/1b, multicenter, single-arm, open-label, dose escalation study to determine the maximum tolerated dose (MTD) and evaluate the safety and preliminary antitumor activity of ACY-241 for oral administration as…
- Trial name
- NCT02400242
- Testing
- ACY-241, Pomalidomide, Dexamethasone
- Where
- 17 sites in United States, France and 3 more
- Volunteers
- 85 people
- Sponsor
- Celgene
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Dual-target CAR-T Cells (C-4-29) in the Treatment of Relapsed/Refractory Multiple Myeloma
This is a phase I clinical study to evaluate the safety and tolerability of C-4-29 in patients with relapsed or refractory multiple myeloma, and to obtain the maximum tolerated dose of C-4-29 and phase II Recommended dose.
- Trial name
- NCT04861480
- Testing
- C-4-29 Cells
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Relapsed or Refractory Multiple Myeloma
QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma
This is a Phase Ib/II, open-label, multi-center and competitive enrollment study of ALT-801 in patients who have relapsed or refractory multiple myeloma.
- Trial name
- NCT01670994
- Testing
- ALT-801
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Altor BioScience
Elranatamab, Myeloma
A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.
The purpose of this study is to understand the study medicine (called Elranatamab, or PF-06863135) as potential treatment for refractory multiple myeloma.
- Conditions
- Elranatamab, Myeloma, Multiple Myeloma, Relapsed Multiple Myeloma
- Trial name
- NCT05228470
- Testing
- Elranatamab
- Where
- 15 sites in China
- Volunteers
- 39 people
- Sponsor
- Pfizer
Lymphoma, Non-Hodgkin, Relapsed Non-Hodgkin Lymphoma
Long-Term Follow-up Study
This is an observational, non-interventional, LTFS of investigational Caribou therapies in patients who have participated in a parent study: a prior Caribou-sponsored clinical study, special access program, or an IIT.
- Conditions
- Lymphoma, Non-Hodgkin, Relapsed Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma
- Trial name
- LTFS (NCT05332054)
- Testing
- Caribou-sponsored investigational therapy
- Where
- 31 sites in United States
- Volunteers
- 150 people
- Sponsor
- Caribou Biosciences, Inc.
Multiple Myeloma
JY232(JY232) Injection in Relapsed/Refractory Multiple Myeloma
This study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed/refractory multiple myeloma.
- Trial name
- NCT07336823
- Testing
- JY232 Injection
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Shenzhen Genocury Biotech Co., Ltd.
Multiple Myeloma
A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent
The purpose of this study is to demonstrate the safety profile of daratumumab in routine clinical practice when given as monotherapy in Indian participants with relapsed and refractory multiple myeloma, whose prior therapy…
- Trial name
- NCT03768960
- Testing
- Daratumumab
- Where
- 16 sites in India
- Volunteers
- 150 people
- Sponsor
- Johnson & Johnson Private Limited
Multiple Myeloma
A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory Multiple Myeloma
This is a multicenter, open-label, dose-escalation/expansion phase 1/2a study to evaluate the safety, tolerability, pharmacokinetic/pharmacodynamic characteristics and determine the recommended dose of KQ-2003 CAR T-cells for…
- Trial name
- NCT06223646
- Testing
- KQ-2003 CAR T-cells
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Novatim Immune Therapeutics (Zhejiang) Co., Ltd.
Multiple Myeloma Refractory, Multiple Myeloma in Relapse
Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple Myeloma
The main purpose of this study is to find out whether inobrodib, when given with pomalidomide and dexamethasone, works better than standard treatment for people whose multiple myeloma has come back or has not improved after…
- Trial name
- DOMMINO-2 (NCT07772024)
- Testing
- InoPd, Investigator's choice of SAT
- Where
- United States
- Volunteers
- 450 people
- Sponsor
- CellCentric Ltd.
Multiple Myeloma
Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma
This Phase I/IIa clinical study is to test safety and anti-tumor activity of BT062 to define the best dose in treating patients with relapsed or refractory multiple myeloma with multiple doses of BT062.
- Trial name
- NCT01001442
- Testing
- BT062
- Where
- 5 sites in United States
- Volunteers
- 35 people
- Sponsor
- Biotest Pharmaceuticals Corporation
Relapsed and/or Refractory Multiple Myeloma
Assessment of AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma
To confirm the maximum tolerated dose (MTD) from the BI 836909 trial of 400 mcg/d, given as 28-day continuous intravenous infusion in patients with relapsed and/or refractory multiple myeloma, to test the 600 mcg/d dose, given as…
- Trial name
- AMG420 (NCT03836053)
- Testing
- AMG 420
- Where
- 10 sites in United States, Australia and 3 more
- Volunteers
- 23 people
- Sponsor
- Amgen
Multiple Myeloma
Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma
This will be a multi-center, open label, expanded treatment protocol of panobinostat, bortezomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma.
- Trial name
- NCT02204553
- Testing
- Panobinostat
- Where
- 27 sites in United States
- Sponsor
- Novartis Pharmaceuticals
Multiple Myeloma in Relapse, Refractory Multiple Myeloma
TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
A phase 3, randomized, open-label, parallel-controlled, multi-center study comparing TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in subjects with relapsed or refractory multiple myeloma who received…
- Trial name
- NCT03952091
- Testing
- TJ202, Lenalidomide and Dexamethasone, Lenalidomide and Dexamethasone
- Where
- 41 sites in China, Taiwan
- Volunteers
- 289 people
- Sponsor
- TJ Biopharma Co., Ltd.
Relapsed, Refractory Multiple Myeloma
RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma
RAPA-201-RRMM is an open-label, single-arm, non-randomized multicenter phase II study of RAPA-201 autologous T cells in adults with relapsed, refractory multiple myeloma who have received at least three (3) prior lines.
- Trial name
- NCT04176380
- Testing
- RAPA-201 Autologous T cells
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Rapa Therapeutics LLC